Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-23-025901

Chief Executive Officer sold 25,000 shares at an average $50.67 ($1,266,638)

  • Chief Executive Officer acquired 25,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2023-04-25 Option exercise 10b5-1 +25,000 $19.12 $478,000 412,377 D
Kulkarni Samarth Chief Executive Officer 2023-04-25 Sale 10b5-1 −20,607 $50.50 $1,040,616 391,770 D
Kulkarni Samarth Chief Executive Officer 2023-04-25 Sale 10b5-1 −4,393 $51.45 $226,021 387,377 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2023-04-25 Option exercise · Stock Option (Right to Buy) 10b5-1 −25,000 104,582 D
Open-market sales · 25,000 sh · avg $50.67 · $1,266,638
Loading xslF345X04/doc4.xml…